Microdosing Tirzepatide Dose Chart: How People Titrate (and the Risks)

If you search for a "microdosing tirzepatide dose chart," you will find dozens of them — neat tables of milligram amounts and weekly schedules shared in forums, on social media, and by some compounding-pharmacy marketing. This page collects what those charts actually say, places them next to the real, FDA-approved dose ladder, and is honest about something most of them leave out: **none of these microdose schemes has been tested in a clinical trial, none is a recognized medical protocol, and the practice carries specific, documented risks.** This is a description of what people do — it is **not medical advice and not a recommendation to do it.**

We'll show the approved ladder first (because that's the only schedule with evidence behind it), then the microdose schemes people circulate, then exactly where the danger lives.

First, a warning before any chart

There is no medical definition of a tirzepatide "microdose," and there is no trial of intentional microdosing. The only clinical literature that addresses the practice directly is **cautionary** — it describes a trend driven by patient anecdotes that emerged amid GLP-1 compounding restrictions, and it warns specifically about dosing errors, pen manipulation, medication sharing, and unregulated sourcing¹¹. So every "dose chart" below should be read as *what people report doing*, not as a validated regimen. We lay out the full evidence picture in our pillar, Microdosing Tirzepatide: what the evidence actually says.

The only chart with evidence behind it: the FDA dose ladder

Before looking at any microdose scheme, it helps to know the real, approved titration schedule — because every microdose chart is defined relative to it. Tirzepatide (sold as Zepbound for weight management and Mounjaro for type 2 diabetes) has an FDA-approved dose ladder that starts low and steps up slowly, specifically to let the gut adapt¹³:

- **Weeks 1–4:** 2.5 mg once weekly (a starting/initiation dose, not a maintenance dose) - **Weeks 5–8:** 5 mg once weekly - **Then, in 2.5 mg steps no sooner than every 4 weeks:** 7.5 mg → 10 mg → 12.5 mg → 15 mg - **Maintenance options:** 5, 10, or 15 mg once weekly; **maximum 15 mg once weekly**¹³

Two things matter here. First, the lowest *approved* dose is 2.5 mg, and even that is meant as a temporary starting rung, not a destination. Second, tirzepatide has a long half-life of roughly 5 days, which is why it is dosed once weekly¹³. A "microdose," by definition, sits **below** the 2.5 mg starting rung — an amount the label never describes and no trial ever tested.

The microdose schemes people actually circulate

The charts shared online generally take one of a few forms. We're reproducing the *patterns* people describe — not endorsing any number — so you can recognize them for what they are.

**1. Fractional weekly dosing.** The most common scheme takes a fraction of the 2.5 mg starting dose — people describe amounts like 0.5–1.5 mg once weekly — and sometimes "holds" there indefinitely instead of titrating up. The pitch is gentler side effects and lower cost. There is no trial of this, and dose-response data (below) predict it does less.

**2. Split or more-frequent dosing.** Some split a weekly amount into smaller doses taken two or three times a week (e.g., several tenths of a milligram per injection). The stated rationale is "smoother levels," but tirzepatide's ~5-day half-life already produces steady weekly levels¹³, so this is a preference, not a pharmacologic necessity — and it multiplies the number of hands-on measurements, which is where errors happen.

**3. "Units" off an insulin syringe.** Because microdosing is almost always done from a **compounded multi-dose vial**, charts often translate milligrams into "units" on a U-100 insulin syringe. This is the single most error-prone step in the whole practice: the conversion depends entirely on the vial's concentration (mg per mL), which varies between compounders and is sometimes mislabeled or uncertain. A chart that says "draw 5 units" is meaningless — and dangerous — unless the exact vial concentration is known and verified.

**4. Pen "clicks."** Some try to dial fractional amounts out of a single-dose or prefilled pen by counting clicks or partial turns. Tirzepatide pens are **not designed for fractional dosing**, and manipulating them is exactly the kind of "pen manipulation" the cautionary literature flags as a source of dosing error¹¹.

We dig into the question of whether any of this produces results in does microdosing GLP-1 actually work.

What the dose-response data predict these charts will do

Here is the inconvenient part for every microdose chart: the best dose-finding evidence says **less drug does less**. The clearest single source is a phase 2 dose-ranging trial of semaglutide for weight loss, where mean weight loss scaled cleanly with dose⁶:

- Placebo: about −2.3% - 0.05 mg: about −6.0% - 0.1 mg: about −8.6% - 0.2 mg: about −11.6% - 0.3 mg: about −11.2% - 0.4 mg: about −13.8%

Tirzepatide shows the same gradient in its own trials: in SURMOUNT-1 the 5, 10, and 15 mg tiers produced roughly 15–21% weight loss, with the higher tiers doing more³, and in the head-to-head SURPASS-2 the effect again climbed with dose⁵. A microdose sits at the very bottom of that curve. So the honest read of these charts is that they describe **smaller-effect** regimens, not a clever shortcut to full-dose results. We walk through the numbers in GLP-1 dose-response: why lower doses do less.

There's a second catch for the "tiny maintenance dose" idea: the benefit tracks ongoing, adequate exposure. In the STEP 4 trial, people who stopped semaglutide regained weight while those who continued held their loss⁷ — which means a dose low enough to be a "microdose" may simply be too low to reach or hold a meaningful effect in the first place.

Where the real risk lives in these charts

A lower number on a chart is not the same as lower risk. Two distinct risk layers stack up.

**The drug-class risks don't vanish at low doses.** A large real-world analysis linked GLP-1 receptor agonists used for weight loss to elevated risk of pancreatitis, bowel obstruction, and gastroparesis¹⁰. Nausea, vomiting, and constipation are mechanistic consequences of GLP-1 action (slowed gastric emptying), not purely a function of dose.

**The microdosing-specific risks are mostly about measurement and sourcing.** Because these charts are executed with compounded vials and DIY math, the dangerous failure modes are preparation and dosing errors. A pharmacovigilance analysis of compounded GLP-1 agonists using the FDA Adverse Event Reporting System found markedly elevated reporting odds for **preparation errors (reporting odds ratio about 48.9), contamination (about 19.0), compounding issues (about 8.5), and prescribing errors (about 4.5)**, plus more reports of abdominal pain, cholecystitis, and hospitalization¹². Those are association signals from a reporting database, not proof of causation — but they point in a worrying direction, and they land hardest exactly when someone is trying to measure a sliver of a milligram out of a vial whose true concentration may be uncertain¹¹. We cover this in depth in is compounded / microdosed GLP-1 safe.

The practical upshot: the most dangerous line in any microdose chart isn't the milligram target — it's the unit-conversion step that assumes you know your vial's concentration. Get that wrong by a factor of ten and a "microdose" becomes a large overdose.

The honest bottom line

Microdose dose charts are easy to find and impossible to verify. The only schedule with trial evidence behind it is the **approved 2.5 → 15 mg ladder**, and even that lowest rung is a temporary starting dose, not a microdose. The fractional, split, "units," and "clicks" schemes people share are untested, off-label, and built on a measurement step that is genuinely error-prone — and the dose-response data say they'd do less anyway. If you are weighing any of this, treat the charts as a description of a risky trend, not a prescription, and talk to a qualified clinician.

For the fuller picture, see our pillar Microdosing Tirzepatide: what the evidence actually says, the dose-response deep dive why lower doses do less, the question does microdosing GLP-1 actually work, and the safety review is compounded / microdosed GLP-1 safe. To see how providers compare on price and oversight, we rank them on our GLP-1 microdose rankings hub.